Companies in system: 2180
Top Biotech Picks
Live rankings pulled from the quantitative scoring model. Use the filters below to hone in on your targets.
Ticker Search
Powered by Alpha Vantage
Advanced Filters
25 of 25 companies shown
| # | Ticker | Asset | Score | Market Cap | P(Up) | Expected Up | Expected Down | Next Catalyst |
|---|---|---|---|---|---|---|---|---|
| 1 | MRNA | mRNA-1273 | 4.258 | $9.9B | 60.0% | 25.0% | 40.0% | 12/27/2025 Data Readout |
| 2 | CRSP | CRISPR-Cas9 Gene Editing Therapy | 3.982 | $4.2B | 60.0% | 25.0% | 40.0% | 12/27/2025 Data Readout |
| 3 | GILD | Bictegravir | 3.558 | $146.3B | 60.0% | 25.0% | 40.0% | 12/27/2025 Data Readout |
| 4 | MRNA | mRNA-4157 | 3.148 | $9.9B | 40.0% | 15.0% | 50.0% | 12/27/2025 Data Readout |
| 5 | GILD | Remdesivir | 2.466 | $146.3B | 60.0% | 25.0% | 40.0% | 12/27/2025 Data Readout |
| 6 | GILD | Bictegravir | 2.429 | $146.3B | 60.0% | 25.0% | 40.0% | 12/28/2025 Data Readout |
| 7 | GILD | Cobicistat | 2.221 | $146.3B | 40.0% | 15.0% | 50.0% | 12/27/2025 Data Readout |
| 8 | RSSS | Other: Point-of-care screening | 0.559 | $104M | 0.0% | 0.0% | 0.0% | — |
| 9 | STEM | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) | 0.477 | $195M | 0.0% | 0.0% | 0.0% | — |
| 10 | AVIR | Bemnifosbuvir (BEM) | 0.466 | $255M | 0.0% | 0.0% | 0.0% | — |
| 11 | KURA | Ziftomenib, Venetoclax, Azacitidine, Cytarabine, Daunorubicin | 0.457 | $891M | 0.0% | 0.0% | 0.0% | — |
| 12 | ACHV | Custirsen, Docetaxel, Prednisone | 0.449 | $243M | 0.0% | 0.0% | 0.0% | — |
| 13 | BNTX | Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX | 0.449 | $25.1B | 0.0% | 0.0% | 0.0% | — |
| 14 | CVM | LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) | 0.447 | $57M | 0.0% | 0.0% | 0.0% | — |
| 15 | ACRS | A-101 Topical Solution | 0.447 | $258M | 0.0% | 0.0% | 0.0% | — |
| 16 | CADL | Biological: Aglatimagene besadenovec + valacyclovir | 0.441 | $295M | 0.0% | 0.0% | 0.0% | — |
| 17 | APLT | Drug: AT-001 | 0.440 | $182M | 0.0% | 0.0% | 0.0% | — |
| 18 | IOVA | Biological: Lifileucel plus Pembrolizumab | 0.440 | $713M | 0.0% | 0.0% | 0.0% | — |
| 19 | ARVN | ARV-471 | 0.438 | $744M | 0.0% | 0.0% | 0.0% | — |
| 20 | ABEO | MSI-78, ofloxacin | 0.437 | $267M | 0.0% | 0.0% | 0.0% | — |
| 21 | BYSI | Docetaxel + Plinabulin | 0.436 | $75M | 0.0% | 0.0% | 0.0% | — |
| 22 | ANVS | Buntanetap/Posiphen | 0.435 | $48M | 0.0% | 0.0% | 0.0% | — |
| 23 | ANL | Buparlisib & Paclitaxel | 0.434 | $56M | 0.0% | 0.0% | 0.0% | — |
| 24 | KOD | KSI-301 | 0.434 | $957M | 0.0% | 0.0% | 0.0% | — |
| 25 | BMY | BMS-986393 | 0.433 | $87.2B | 0.0% | 0.0% | 0.0% | — |